retatrutide ly3437943 parkinson's disease clinical trial 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most A Study of Retatrutide (LY3437943)

Scientific research shows Mat to be a powerful antioxidant and that it can protect DNA from double-strand breaks

Its pharmacokinetics are influenced by factors such as renal function, genetics, sex, and age

Furthermore, the ad also provoked two senators, a Democrat (Dick Durbin, D-IL) and Republican (Roger Marshall, MD, R-KS), to write the FDA a letter expressing the legislators concerns about the lack of safety information in the ad threatening potential enforcement action

Read the Houston Chronicle's full investigative series on Houston-based Empower Pharmacy, one of the largest compounding pharmacies in the U.S.